

## IN THE CLAIMS

1. (Previously Presented) A pharmaceutical composition for cancer therapy consisting essentially of:
  - a) at least one compound having glutaminase activity;
  - b) at least one antineoplastic agent selected from the group consisting of platinum complexes and anthracyclines; and
  - c) at least one of carrier substances, auxiliary substances, and pharmaceutical injection media.
2. (Previously Presented) The composition of claim 1, wherein said at least one compound having glutaminase activity is a glutaminase, glutaminase-asparaginase, glutaminase analogue, derivative or modification thereof and is either of natural origin or is produced synthetically.
3. (Previously Presented) The composition of claim 2, wherein said at least one compound having glutaminase activity is Pseudomonas 7A glutaminase-asparaginase.
4. (Previously Presented) The composition of claim 1, wherein said at least one compound having glutaminase activity is modified with polyethylene glycol.
5. (Currently Amended) The composition of claim 1, wherein said anthracyclines comprise at least one of doxorubicin, daunomycin, actinomycin D [[and]] or mitoxantrone.
6. (Currently Amended) The composition of claim 1, wherein said platinum complexes comprise at least one of cis-platinum, oxaliplatinum [[and]] or carboplatinum.
7. (Previously Presented) A process for producing the pharmaceutical composition as claimed in claim 1, wherein said active substances are processed into oral or parenteral forms of administration.

8. (Withdrawn) Use of in particular a compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes and anthracyclines to produce an agent for an antineoplastic therapy.

9. (Withdrawn) Method for treating cancer and other diseases which are associated with abnormal cell proliferation, characterized in that at least one compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes or anthracyclines are administered in a molar ratio between 1:10 to 1:1000 and 10:1 to 1000:1, where the doses to be administered daily are 0.005 – 100 mg/kg body weight per individual component.

10. (Previously Presented) The process of claim 7, wherein said active substances are mixed together with common pharmaceutical carrier substances or auxiliary substances.

11. (Canceled)

12. (Previously Presented) The composition of claim 1, wherein said platinum complexes are cis-platinum.

13. (Previously Presented) A pharmaceutical composition for cancer therapy consisting essentially of:

a) at least one compound having glutaminase activity consisting of a tetramer composed of four subunits with a molecular weight of approximately 35 KDa;

b) at least one antineoplastic agent selected from the group consisting of platinum complexes and anthracyclines; and

c) at least one of carrier substances, auxiliary substances, and pharmaceutical injection media.

14. (New) The composition of claim 13, wherein the pharmaceutical composition has a therapeutic dose of glutaminase activity from 50-150 I.U./m<sup>2</sup>.